Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
-
Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress
-
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
-
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL at ASCO
-
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
-
Autolus Therapeutics announces acceptance of MAA by the EMA for obe-cel for patients with B-ALL
-
Autolus Therapeutics Announces Changes to its Board of Directors
-
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
-
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
-
Autolus Therapeutics announces publication in Blood Cancer Journal